Anti-VEGFR2 therapy delays growth of preclinical pediatric tumor models and enhances anti-tumor activity of chemotherapy.

Saved in:
Bibliographic Details
Title: Anti-VEGFR2 therapy delays growth of preclinical pediatric tumor models and enhances anti-tumor activity of chemotherapy.
Authors: Lowery CD; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA., Blosser W; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA., Dowless M; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA., Renschler M; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA., Perez LV; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA., Stephens J; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA., Pytowski B; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA., Wasserstrom H; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA., Stancato LF; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA., Falcon B; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA.
Source: Oncotarget [Oncotarget] 2019 Sep 17; Vol. 10 (53), pp. 5523-5533. Date of Electronic Publication: 2019 Sep 17 (Print Publication: 2019).
Publication Type: Journal Article
Journal Info: Publisher: Impact Journals Country of Publication: United States NLM ID: 101532965 Publication Model: eCollection Cited Medium: Internet ISSN: 1949-2553 (Electronic) Linking ISSN: 19492553 NLM ISO Abbreviation: Oncotarget Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1949-2553
DOI:10.18632/oncotarget.27148